Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2020-11-05 AGM Information
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
AGM Chairman's Address and CEO Presentation 13 pages 584.6KB
AGM Information Classification · 95% confidence The document is titled '2020 AGM Chairman's Address and CEO Presentation' and is explicitly stated to be materials to be made at the 2020 Annual General Meeting (AGM). It contains a Chairman's address, CEO presentation slides, and detailed information about the company's progress, milestones, and future plans. The content is consistent with presentations and materials shared during an AGM rather than a full annual report or other filing types. The document length is about 11,691 characters, which is substantial and contains detailed presentation content. Therefore, the document fits the category of AGM Information (AGM-R).
2020-11-05 English
Results of Annual General Meeting 2 pages 116.2KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Results of 2020 Annual General Meeting' and provides detailed voting results for resolutions passed at the AGM held on 6 November 2020. It references the Corporations Act and Listing Rule 3.13.2, indicating compliance with regulatory requirements for reporting voting outcomes. The content focuses exclusively on the results of shareholder votes on various resolutions, including remuneration, election of directors, approval of incentive plans, takeover provisions, and a new constitution. There is no financial data, management discussion, or presentation material included. The document is relatively short (4462 characters) and serves as an official announcement of voting results rather than the AGM materials themselves or the full annual report. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA).
2020-11-05 English
New Constitution 67 pages 2.6MB
Regulatory Filings
2020-11-05 English
Grants Awarded to Support Clinical Progression of Lead Drug 2 pages 222.4KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 29 October 2020 regarding grants awarded to support clinical progression of the company's lead drug. It discusses funding amounts and the purpose of the grants but does not contain financial statements, earnings data, or detailed financial analysis. It is a brief announcement about financing support related to research and development activities. The document length is 3071 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication of it being an earnings release, annual or interim report, or other detailed financial filing. The content fits best under Capital/Financing Update (CAP) as it relates to updates on company fundraising or financing activities, specifically grants awarded to the company.
2020-10-28 English
Change in substantial holding 3 pages 100.4KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 604 Corporations Act 2001 Section 671B Notice of change of interests of substantial holder.' It details changes in voting power and relevant interests of a substantial shareholder in PYC Therapeutics Limited, including dates and share counts. This form is a regulatory notification about changes in significant share ownership levels, consistent with the definition of Major Shareholding Notification (MRQ). The document is not a financial report, earnings release, or management report, but a formal notice of shareholding changes under regulatory requirements.
2020-10-27 English
Change of Director's Interest Notice x 2 5 pages 469.1KB
Director's Dealing Classification · 100% confidence The document is an ASX announcement dated 28 October 2020, titled 'Change in Director’s Interest Notice x 2'. It contains detailed information about changes in shareholdings of two directors, Alan Tribe and Bernard Hockings, including the number of shares held before and after the change, the nature of the change (participation in an accelerated component of a non-renounceable entitlement issue), and other related details. The document references Appendix 3Y, which is a standard form used in Australian securities regulation for notifying changes in directors' interests. There is no financial performance data, earnings information, or management discussion. The document is clearly a report of personal share transactions by company directors. Therefore, it fits the category of Director's Dealing (DIRS). The document length (8926 characters) and content confirm it is the actual notice, not just an announcement of a report publication or a certification. Confidence is high due to the explicit nature of the content and regulatory references.
2020-10-27 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.